Nachrichten zur Johnson & Johnson Aktie

Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump

The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the companys biggest shake-up in…

Surgical Dressing Market Valuation to Reach US$1.9 Billion by 2030, Driven by 6.1% CAGR | Persistence Market Research

Discover the dynamic world of the surgical dressing market with a comprehensive market overview. Explore key statistics, technology trends, market…

Johnson & Johnson Is a Changed Company. What to Expect From Earnings.

…

Global Hand Wash Market Size To Exceed USD 7.23 Billion By 2032 | CAGR of 7.1%

The Global Hand Wash Market Size was valued at USD 3.62 Billion in 2022 and the Worldwide Hand Wash Market…

New ADHD drugs could pay off for pharmaceutical companies (NASDAQ:AXSM)

Pharmaceutical companies would be wise to pay attention to developing new treatments for ADHD as there is a demand for…

Earnings week ahead: Tesla, Netflix, AT&T, Johnson & Johnson, GE and more

…

Wochenausblick - Die Quartalssaison steht in den Startlöchern.

WerbungZum Start in die neue Börsenwoche informieren wir jeden Sonntag über Wirtschaftsdaten, Quartalszahlen und mehr. Neben den Quartalszahlen von Netflix,…

Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa

…

Window Film Market to reach $96.9 Bn by 2032, Says Global Market Insights Inc.

Major window film market participants include Eastman Chemical Company (LLumar), 3M Company, Saint-Gobain Performance Plastics (Solar Gard), Avery Dennison, Madico,…

Top 5 Life Science ETFs

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…

Johnson & Johnson likely to post dip in 4Q earnings

Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its…

Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?

…

Johnson Controls names new finance chief

…

Johnson & Johnson: One Penny, Per Hour, Forever

…

S&P 500 zum Teil geschlagen: 15 Dividendenkönige, die seit 60 Jahren oder mehr ihre Ausschüttungen erhöhen

Diese 15 Aktienunternehmen, darunter Namen wie Procter & Gamble und Johnson & Johnson, haben ihre Dividenden seit mehr als 60…

Johnson & Johnsons Acquisition Of Ambrx Biopharma: Hold Through It

…

The Zacks Analyst Blog Highlights Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR

Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR are part of the Zacks top Analyst Blog.…

Johnson & Johnson-Aktie mit leichten Kursgewinnen (147,4645 €)

Die Aktie von Johnson & Johnson notiert heute etwas fester. Zuletzt zahlten Investoren für das Papier 161,77 US-Dollar. Am Aktienmarkt…

Is Johnson & Johnson Stock a Buy Now? @themotleyfool #stocks $JNJ

The pharmaceutical giant recently announced another acquisition.…

Is Johnson & Johnson Stock a Buy Now?

The pharmaceutical giant recently announced another acquisition.…

Top Analyst Reports for Johnson & Johnson, Micron Technology & Southern Company

Todays Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU)…

Ambrx Holders Who Bought for Pennies See 6,700% Gain on J&J Bid

Longtime believers in Ambrx Biopharma Inc. are being rewarded with juicy returns as Johnson & Johnson’s buyout offer values the…

Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business

…

This Dividend Stock Has a $13 Billion Secret Weapon @themotleyfool #stocks $JNJ

Johnson & Johnson made a key decision last year.…

Bile Duct Cancer Treatment Market Trends and Forecast 2031 - Market Set for Significant Growth by 2031 Amid Rising Incidences and Technological Advancements

Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Bile Duct Cancer Treatment Market - Global Industry Analysis, Size,…

Johnson & Johnson (JNJ) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

Johnson & Johnson to acquire Ambrx Biopharma for $2 billion By Investing.com

Johnson & Johnson to acquire Ambrx Biopharma for $2 billion…

Johnson & Johnson: EPS Growth Returns In 2024, JPM Healthcare Conference On Tap

…

Johnson & Johnson erwirbt das Biotech Unternehmen Ambrx für 2 Milliarden Dollar

…

Johnson & Johnson: Übernahme lässt diese Aktie explodieren

Johnson & Johnson hat einen entscheidenden Schritt zur Erweiterung seines Onkologie-Portfolios unternommen, indem das Unternehmen die Absicht zur Akquisition eines…

Johnson & Johnson schlägt zu – 100 Prozent Aufschlag

Johnson & Johnson (J&J) wird 2,0 Milliarden Dollar in bar zahlen, um Ambrx Biopharma zu erwerben und damit einen Entwickler…

PRTG: Bridging I-O: Working in Harmony with Checkpoints

By John Vandermosten, CFA NASDAQ:PRTG READ THE FULL PRTG RESEARCH REPORT We are initiating coverage of Portage Biotech Inc. (NASDAQ:PRTG) with a target…

Johnson & Johnson: 2,0 Milliarden Dollar für Ambrx Biopharma - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von "Der Aktionär": Michael Diertl vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die…

Johnson & Johnson: Übernahme lässt diese Aktie explodieren

Johnson & Johnson plant die Übernahme eines Biotechnologieunternehmens für zwei Milliarden US-Dollar, um sein Onkologie-Portfolio zu erweitern.…

Johnson & Johnson to acquire Ambrx for $2B

Johnson & Johnson (NYSE:JNJ) has announced its definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company, in an all-cash...…

Johnson & Johnson to acquire Ambrx in $2 billion deal

…

Johnson & Johnson to Acquire Ambrx for $2 billion By Investing.com

Johnson & Johnson to Acquire Ambrx for $2 billion…

Ambrx Announces Sale to Johnson & Johnson

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that…

Johnson & Johnson: Kursziel gekürzt

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays stufen die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046, WKN: 853260, Ticker-Symbol:…